Author: Ackerman, M.; Henry, D.; Finon, A.; Binois, R.; Esteve, E.
Title: Persistent maculopapular rash after the first dose of Pfizerâ€BioNTech COVIDâ€19 vaccine Cord-id: ojnr7n2z Document date: 2021_4_8
ID: ojnr7n2z
Snippet: The ongoing global pandemic COVID-19 led regulatory agencies to recently issue an emergency authorization for two effective Covid-19 vaccines from Pfizer-BioNTech and Moderna. Both vaccines use a novel technology of administering vaccination, namely a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the spike glycoprotein of SARS-CoV-2 for subsequent antigen presentation and immune system activation (1).
Document: The ongoing global pandemic COVID-19 led regulatory agencies to recently issue an emergency authorization for two effective Covid-19 vaccines from Pfizer-BioNTech and Moderna. Both vaccines use a novel technology of administering vaccination, namely a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the spike glycoprotein of SARS-CoV-2 for subsequent antigen presentation and immune system activation (1).
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date